Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in prostate cancer
- Trial result
Prostate cancer
Olaparib (PARP inhibitor) + Abiraterone (CYP17 AR-pathway inhibitor) Extends rPFS in Non‑BRCA mCRPC (PROpel)
Olaparib is an oral PARP inhibitor combined with abiraterone, an androgen-biosynthesis (CYP17) inhibitor, and tested in the Phase 3 double-blind PROpel trial (NCT03732820) as first-line therapy for metastatic…
NCT03732820 - New trial Spotlight
Prostate cancer
Phase 1 JANX013 PSMA×CD28 costimulation combines with JANX007 PSMA×CD3 T-cell engagement
Janux Therapeutics’ first-in-human Phase 1, open-label, multicenter study evaluates JANX013 plus JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC). JANX007 is a PSMA-directed,…
NCT07813637 First-in-human - New trial
Prostate cancer
Phase 2 JNJ-101556143 uses an AR-BRD4 induced-proximity mechanism in resistant prostate cancer
This Phase 2, open-label, multicenter, single-arm study tests once-daily oral JNJ-101556143, previously called HLD-0915, in metastatic androgen pathway modulation-resistant prostate cancer. The primary activity…
NCT07832292 Exploratory - New trial
Prostate cancer
Phase 1a/1b JUR-003 KLK2×CD3 bispecific T‑cell engager in metastatic prostate cancer
JUR-003-ONC-101 is a first-in-human, open-label, multicenter Phase 1a/1b study testing JUR-003, a KLK2×CD3 bispecific monoclonal antibody designed to bind prostate tumor–associated kallikrein-related peptidase 2…
NCT07824349 First-in-human - New trial Spotlight
Prostate cancer
Phase 1 FH-STEAP1 IL-18 CAR T tests STEAP1-targeted CAR-T armored with IL-18
Fred Hutchinson Cancer Center is running a first-in-human Phase 1 dose-escalation/expansion study of FH-STEAP1 IL-18 CAR T cells, an autologous anti-STEAP1 CAR-T therapy engineered to secrete IL-18 (a…
NCT07803653 First-in-human - New trial
Prostate cancer
Phase 2 ADT (GnRH antagonist/agonist) + ultra-hypofractionated SBRT in ARTERA-low high-risk prostate cancer
NYU Langone Health is running this single-arm, open-label Phase 2 trial testing whether short-course androgen deprivation therapy (ADT) for 6 months can be paired with dose-escalated radiotherapy…
NCT07801664 Exploratory - New trial
Prostate cancer
Phase 1/2 onabotulinumtoxinA (BOTOX) neuromuscular blocker (SNARE-mediated ACh release inhibitor) in high-risk prostate cancer
This Phase 1/2 pilot from Houston Methodist (The Methodist Hospital Research Institute) randomizes 30 men 1:1 in a single-blind, placebo-controlled design to a one-time intraprostatic onabotulinumtoxinA injection (50…
NCT07796490 Exploratory - New trial
Prostate cancer
Phase 2 18F-fluorthanatrace (FTT) PARP1-targeted PET tracer to predict PARPi response
Washington University School of Medicine is running a multicenter, open-label diagnostic study testing whether 18F-fluorthanatrace (18F-FTT), a PARP1-directed PET imaging tracer, can help predict response to…
NCT07723651 Exploratory - New trial Spotlight
Prostate cancer
Phase 1/2 ADI-212 PSMA-targeted γδ (Vδ1) CAR-T cells in mCRPC.
This Phase 1/2 multicenter, open-label, dose-escalation (3+3) and dose-expansion study evaluates ADI-212, an allogeneic engineered γδ (Vδ1) CAR-T cell therapy that targets PSMA on prostate cancer cells, sponsored by…
NCT07793435 First-in-human - New trial
Prostate cancer
MR-guided focal SBRT uses MRI target localization to deliver high-dose hypofractionated radiation.
This City of Hope Medical Center pilot evaluates focal magnetic resonance–guided stereotactic body radiation therapy (MR-guided SBRT), a device-enabled radiation approach (not a drug) that uses on-table MRI to…
NCT07769372 Exploratory - Trial result
Prostate cancer
Enzalutamide (AR inhibitor) + testosterone suppression extends 8-year OS in mHSPC vs first-gen NSAAs (ENZAMET)
Enzalutamide is a potent androgen receptor (AR) signaling inhibitor, and in the ENZAMET Phase 3 trial (NCT02446405) it was added to testosterone suppression (ADT) and compared against ADT + a first-generation…
NCT02446405 - New trial Spotlight
Prostate cancer
Phase 2 MRT-2359 GSPT1 molecular glue degrader + apalutamide AR inhibitor in AR-mutant mCRPC.
This Phase 2 open-label, multicenter study (MODeFIRe-1) from Monte Rosa Therapeutics tests oral MRT-2359 plus apalutamide in patients with castration-resistant prostate adenocarcinoma whose tumors harbor androgen…
NCT07745361 Exploratory - New trial
Prostate cancer
Phase 1b sipuleucel‑T + N‑803 trial tests PAP vaccine plus IL‑15 superagonist immunostimulation
Washington University School of Medicine is running a single-center, open-label Phase 1b, modified 3+3 de-escalation study to define safety, tolerability, and the recommended Phase 2 dose for combining sipuleucel‑T…
NCT07756593 Exploratory - New trial
Prostate cancer
Phase 2 BALANCE-RT compares HDR brachytherapy boost vs SBRT alone (radiation intensification).
Memorial Sloan Kettering Cancer Center is running BALANCE-RT (NCT07751159) to test whether adding an HDR brachytherapy boost (temporary internal radiation that delivers very high dose inside the prostate) to SBRT…
NCT07751159 Exploratory - Trial result Spotlight
Prostate cancer
Olaparib (PARP inhibitor) + Abiraterone Shows BRCA2-Driven Benefit in 1L mCRPC
Olaparib is an oral PARP inhibitor combined here with abiraterone, a CYP17 androgen-biosynthesis inhibitor, plus prednisone/prednisolone in the randomized, double-blind Phase 3 PROpel trial (NCT03732820) in…
NCT03732820 - Trial result
Prostate cancer
NRG-GU005: 5-fraction SBRT improves bowel QOL but does not improve 3-year DFS vs MH-IMRT.
SBRT is an ultra-hypofractionated, image-guided radiotherapy regimen (36.25Gy/5 fractions) compared head-to-head with moderately hypofractionated IMRT (70Gy/28 or 60Gy/20) in the Phase 3, international, open-label…
NCT03367702 - Trial result
Prostate cancer
Darolutamide (AR antagonist) + ADT cuts rPFS risk across high- and low-volume mHSPC in ARANOTE
Darolutamide is an oral androgen-receptor inhibitor evaluated with androgen-deprivation therapy (ADT) vs placebo + ADT in the Phase 3 ARANOTE trial (NCT04736199) in metastatic hormone-sensitive prostate cancer…
NCT04736199 - New trial
Prostate cancer
Phase 2 zanzalintinib (MET/VEGFR2/AXL/MER TKI) in aggressive-variant prostate cancer
This multicenter, single-arm Phase 2 NAPOLEON study evaluates the antitumor activity of oral zanzalintinib 60 mg once daily in men with aggressive variant prostate cancer (AVPC), using a 2‑stage group-sequential…
NCT07218666 Exploratory - New trial Spotlight
Prostate cancer
Phase 1 FX-111 ARON degrader targets transcriptionally active androgen receptor in mCRPC.
This Phase 1, first-in-human, open-label dose-escalation with optional expansion study evaluates FX-111 in adult men with metastatic castration-resistant prostate adenocarcinoma that has progressed on…
NCT07719361 First-in-human - New trial
Prostate cancer
Early Phase 1 semaglutide GLP-1 receptor agonist neoadjuvant metabolic therapy before prostatectomy
Banner Health’s single-arm, open-label exploratory early phase 1 study tests whether preoperative semaglutide can drive measurable biologic changes in intermediate-risk localized prostate cancer during a 3–6 month…
NCT07727473 Exploratory - Trial result
Prostate cancer
RTIRE (IRE focal ablation + reduced-dose RT) yields 100% negative 12‑mo biopsy in intermediate‑risk prostate cancer
RTIRE combines irreversible electroporation (IRE), a nonthermal focal ablation approach, followed by reduced-dose external-beam radiation (32.5Gy in 5 fractions) to treat MRI-visible grade group 2–3 index lesions in…
NCT05345444 - Trial result
Prostate cancer
Talazoparib (PARP inhibitor) + enzalutamide (AR antagonist) shows “early rPFS, late OS” signal in HRR–non-deficient/unknown mCRPC (post hoc)
Talazoparib is an oral PARP inhibitor combined with enzalutamide, an androgen-receptor signaling inhibitor, in first-line metastatic castration-resistant prostate cancer (mCRPC); this post hoc analysis of TALAPRO-2…
NCT03395197 - Trial result
Prostate cancer
pTVG-HP (PAP DNA vaccine) signals OS benefit in PSA-recurrent nonmetastatic prostate cancer vs placebo
pTVG-HP is a plasmid DNA vaccine encoding prostatic acid phosphatase (PAP), administered with GM-CSF, evaluated in a randomized Phase 2 trial in PSA-recurrent, nonmetastatic, noncastrate prostate cancer…
NCT01341652 - Trial result
Prostate cancer
Enzalutamide (AR inhibitor) benefit in mHSPC concentrates in APIC-negative tumors (OS HR 0.50), not APIC-positive (HR 1.04)
APIC is a locked AI histopathology classifier applied to baseline H&E prostate cancer specimens to predict differential benefit from enzalutamide (androgen receptor inhibitor) added to ADT in mHSPC. In this…
NCT02446405 - Trial result
Prostate cancer
Darolutamide (AR antagonist) triplet delays mCRPC (HR 0.36) without worsening pain/QoL in mHSPC
Darolutamide is an oral androgen receptor (AR) antagonist evaluated as “triplet therapy” with androgen deprivation therapy (ADT) plus docetaxel in the Phase III ARASENS trial (NCT02799602) in metastatic…
NCT02799602 - Trial result
Prostate cancer
Ablative MDT (PSMA-PET–guided SBRT) prolongs time to PSA progression in oligometastatic CRPC (interim Phase II)
In a single-centre randomized Phase II trial, PSMA-PET–guided metastasis-directed therapy (MDT; ablative radiotherapy to ≤5 PSMA-positive bone/lymph node metastases) was tested in castration-resistant prostate cancer…
NCT04141709 - New trial Spotlight
Prostate cancer
Phase 3 rinzimetostat (ORIC-944) EED/PRC2 inhibitor + darolutamide AR antagonist in post-abiraterone mCRPC
ORIC Pharmaceuticals’ Himalayas-1 (NCT07723248) is a randomized, open-label Phase 3 study in metastatic castration-resistant prostate cancer (mCRPC) that has progressed after abiraterone acetate, testing whether…
NCT07723248 Registrational - New trial
Prostate cancer
Phase 3 177Lu vipivotide tetraxetan PSMA-targeted beta-emitting radioligand with adaptive dosing (RECIPROCAL)
Alliance for Clinical Trials in Oncology’s RECIPROCAL (A032304; NCT07200830) is a randomized Phase 3 strategy trial asking whether *when* to give additional doses of 177Lu vipivotide tetraxetan (Novartis’…
NCT07200830 Registrational - New trial Spotlight
Prostate cancer
Phase 2 [177Lu]Lu-PSMA-617 radioligand (PSMA-targeted beta emitter) with intermittent ADT
Mayo Clinic is running a randomized Phase 2 study in low-volume metastatic hormone-sensitive prostate cancer (de novo or recurrent after prior local therapy) testing whether adding [177Lu]Lu-PSMA-617 (lutetium Lu 177…
NCT07650240 Exploratory - Trial result Spotlight
Prostate cancer
CAN-2409 (HSV‑tk adenoviral gene therapy) + valacyclovir improves DFS when added to curative EBRT in localized prostate cancer
Aglatimagene besadenovec (CAN-2409) is an intraprostatic, replication-defective adenoviral vector expressing HSV‑thymidine kinase; with valacyclovir it drives tumor cell kill and immunogenic cell death, and was…
NCT01436968
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.